Diabetic Retinopathy (DR) is one of the leading causes of visual impairment and blindness in diabetic patients worldwide. Accurate Computer-Aided Diagnosis (CAD) systems can aid in the early diagnosis ...

Diabetic Retinopathy is a progressive microvascular complication of diabetes that requires early detection to improve patient outcomes. Traditional screening techniques, including fundus photography ...

A deep learning system can accurately detect vision-threatening diabetic retinopathy, demonstrating specialist-level diagnostic performance.

Perfuse Therapeutics' drug-device PER-001 shows promise in treating glaucoma and diabetic retinopathy, potentially restoring vision in patients.

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

OCT-detected retinal layer loss reflects underlying progression in MS, even without relapse or MRI evidence.

By addressing two central drivers of the underlying type 2 inflammation that contributes to bullous pemphigoid, Dupixent is the first targeted medicine to allow patients the potential to achieve ...

FDA approves Dupixent for treating bullous pemphigoid in adults, showing significant improvements in disease management.